Both new drugs for sleep disorders have not entered the new version of the medical insurance catalog and the commercial insurance innovative drug catalog.

It was learned from the scene of the 2025 Conference on High-Quality Development of Innovative Drugs held today that the new drugs for sleep disorders, Libole tablets from Weicai and Daleret tablets from Hainan Xiansheng, have not entered the national medical insurance drug list or the commercial insurance innovative drug list. Both drugs had previously passed the form review of the medical insurance list and the commercial insurance innovative drug list.